The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Salvage treatment options following CAR-T failure in DLBCL
Jaromir Tomasik, Medical University of Warsaw, Warsaw, Poland, discusses a meta-analysis comparing salvage treatment options for patients with diffuse large B-cell lymphoma (DLBCL) who have failed CAR-T therapy. The study found that CAR T-cells targeting antigens other than CD19 had the best outcomes. Bispecific antibodies showed higher response rates than checkpoint or kinase inhibitors, offering another salvage option when non-CD19 CAR T-cells are not available. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
